Adimab, LLC

66 articles with Adimab, LLC

• Ablexis Announces License Agreement with Adimab

  2/9/2023

  Ablexis, LLC today announced a license agreement with Adimab, LLC (“Adimab”).

• Adimab Provides 2022 Update on Clinical Pipeline

  1/11/2023

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that seven new partner programs entered clinical development in 2022, including programs by Biotheus, Dragonfly, Innovent, Surface Oncology, and a program with financial support from the Gates Foundation.

• Adimab Provides Year-End Update on 2022 Partnership Activities

  1/10/2023

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it entered into partnership agreements with 11 new companies in 2022.

• 

  ADC, Adimab and Longeveron Begin New Leadership Chapters

  5/10/2022

  Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.

• Adimab Announces Promotions of New Chief Executive Officer and President

  5/9/2022

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced the appointments of Philip T. Chase as Chief Executive Officer and Eric M. Krauland as President and Chief Scientific Officer.

• 

  Kelonia Scores $50M to Propel In Vivo Gene Delivery Platform

  4/28/2022

  Boston-based Kelonia Therapeutics launched after a successful $50 million Series A round of financing, which will push its research efforts in genetic medicines for immunology and oncology.

• Adimab Announces Launch of Four New Proprietary Technologies

  1/26/2022

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced an expanded offering of proprietary technologies to aid the development of antibody and multispecific therapeutic modalities.

• Adimab Provides 2021 Update on Clinical Pipeline

  1/19/2022

  Adimab, LLC today announced that 12 new partner programs entered clinical development in 2021.

• Adimab Provides Year-End Update on 2021 Partnership Activities

  1/12/2022

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in 2021 it entered into agreements with 13 new companies.

• Adimab Provides Year-End Update on 2020 Partnership Activities

  2/11/2021

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced that in 2020 it entered into agreements with 11 new companies.

• Adimab Extenadimds Platform Partnership with Novo Nordisk

  1/14/2020

  This agreement extends an ongoing partnership between the two companies that began in 2013.

• Adimab Provides 2019 Update on Clinical Pipeline

  1/13/2020

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced that 11 new partner programs entered clinical development in 2019.

• Adimab Expands Research Agreement with Regeneron

  5/8/2019

  Adimab, LLC, the leading provider of antibody discovery and optimization technology, announced the expansion of an earlier multi-target research agreement with Regeneron Pharmaceuticals.

• Adimab Announces Multi-Target Expansion for the Discovery of Antibodies with Another Global Pharma Partner

  5/8/2019

  Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, announced the expansion of an earlier partnership with Novartis.

• Adimab Announces Antibody Discovery Platform Transfer with Takeda

  5/8/2019

  Sixth pharma partner to internalize the Adimab platform

• Adimab Provides 2018 Update on Clinical Pipeline

  1/9/2019

  - 12 New Partner Programs Entered the Clinic in 2018 - - 21 Clinical Trials Initiated to Date -

• Adimab Provides Year-End Update on 2018 Partnership Activities

  1/8/2019

  - Added 17 Partnerships - - Achieved 70 Milestones - - Total of Over 260 Therapeutic Programs at End of 2018

• Adimab Partner Innovent Receives Product Approval for PD-1 Antibody for Hodgkin's Lymphoma

  1/7/2019

  First Adimab Antibody to Enter the Market

• Adimab Initiates Update on Clinical Progression of Partner Programs

  1/11/2018

  Adimab announced that six new partner programs entered clinical trials in 2017.

• Adimab Announces Antibody Discovery Collaboration with Boehringer Ingelheim

  1/10/2018

  Under the terms of the agreement, Adimab will use its proprietary platform to discover and optimize antibodies against targets chosen by BI, who will have the rights to develop and commercialize therapeutic programs resulting from the collaboration.